Jim Kastenmayer – Viela Bio

Biotech and boilerplate: Attorney masters science and law

Imagine strolling through a park splashed with the greens, yellows and reds of trees, grass and flowers. The gravel or woodchips crunch underfoot as you enjoy exercise, sunshine and good health.

Jim Kastenmayer – Viela Bio

Jim Kastenmayer | General Counsel | Viela Bio | Photo Credit: Len Spoden Photography

And suddenly, you can’t see well or have trouble walking.

It could be an attack of a terrifying and debilitating condition called neuromyelitis optica spectrum disorder, where your own immune system barrages your optic nerves, spinal cord and brain stem.

Viela Bio, a biotech company in Gaithersburg, Maryland, has developed a medicine to treat NMOSD.

The new medicine was approved by the U.S. Food and Drug Administration in June 2020. It’s a major milestone for the company, which is dedicated to discovering, developing and commercializing novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases.

Jim Kastenmayer – Viela Bio

Photo Credit: Bryce Vickmark Photography

Because inebilizumab, the antibody in Viela Bio’s new medicine, was shown to reduce the risk of NMOSD relapses without concomitant use of steroids (which can cause significant side effects), it’s a significant breakthrough, according to the company’s first general counsel, Jim Kastenmayer.

And Kastenmayer would know. He’s not just an attorney—he also has a Ph.D. in biochemistry, cell and molecular biology—and he says the potential of treatments like this, and his understanding of them, bring a vibrancy to his work that is never far from the surface.

“Viela has a team very experienced in the discovery, development, and commercialization of medicines, but many of us have taken on new areas of responsibility and are doing some things for the first time,” Kastenmayer says. “I’m surrounded by other people who are learning, who I’m learning from, and who are committed to doing well and growing as they do.”

Well founded

Viela Bio was founded with assets spun out of pharmaceutical giant AstraZeneca, both human and molecular. Inebilizumab is its lead asset, and there’s a pipeline of clinical and pre-clinical innovative molecules focused on shared critical biological pathways of autoimmune diseases, Kastenmayer says.

He was pleased to discover how well the company’s external legal team at Mintz Levin had positioned Viela Bio for welcoming its first general counsel after shepherding the company through its recent IPO. And while he has a deep appreciation for the science, Kastenmayer’s been very busy setting the stage for Viela Bio’s emergence on the market.

Jim Kastenmayer – Viela Bio

Photo Credit: Bryce Vickmark Photography

As Viela Bio onboards and deploys its sales, medical, and market access professionals, it enters a highly regulated industry, he explains. So Kastenmayer is creating the compliance program to ensure the company’s field activities meet requirements guarding against fraud and abuse.

And because Viela Bio just became publicly traded, Kastenmayer helped file its first disclosures with the U.S. Securities and Exchange Commission. As company secretary, he’s also supporting the board of directors, noting their increased interest in the company’s progress in bringing its first medicine to patients.

The company is researching whether Inebilizumab works in additional diseases, and Kastenmayer’s team is in charge of protecting IP arising from those studies, as well as IP from development and manufacturing and the other assets in Viela Bio’s pipeline.

“We pride ourselves on being a small and nimble biotech,” though one with global ambitions, Kastenmayer says.

Kastenmayer has  participated in meetings with commercial partners in Asia, has worked to establish European Viela corporate entities, and looks forward to potential approvals of Inebilizumab outside the U.S. in the coming years.

Of treatises and treatments

Kastenmayer say he’s long been fascinated by the intersection of law, business and science, and his work of late has blended them in ways he could not have imagined.

After an itinerant childhood in an army family, he earned his Bachelor’s in biology at the University of Virginia. His Ph.D. in biochemistry, cell and molecular biology, is from Michigan State University, where he was also a postdoctoral fellow.

Jim Kastenmayer – Viela Bio

Photo Credit: Bryce Vickmark Photography

“I was already intrigued with patent law, so I took and passed the patent bar during this time,” Kastenmayer says.

He joined the National Cancer Institute as a postdoctoral fellow and later became a technology transfer fellow at the National Institutes of Health. He also began law school in the evening and eventually earned his J.D. from Georgetown University Law Center.

While in school, he went to work as a student associate at the law firm of Finnegan Henderson, gaining a deep knowledge of patent prosecution and litigation. He recalls the firm as a great place to work on cutting edge IP issues with a team of some of the most experienced lawyers in the field, but the pace Kastenmayer set for himself was exhausting.

“Although rewarding, it was tough working during the day and going to school in the evening,” he says. “It was probably the only thing where I thought if ‘I had to do this again, I wonder if I would have done it differently.’”

Jim Kastenmayer – Viela Bio

Photo Credit: Bryce Vickmark Photography

After earning his J.D., Kastenmayer became a patent attorney at the firm, and subsequently entered the biotech field as IP counsel at MedImmune, where he spent honed his in-house skills as a patent attorney for several potential medicines.

He next joined AstraZeneca as a senior patent director, reuniting him with the lawyer who had headed the IP team at MedImmune, and who continued to have a major positive impact on Kastenmayer’s development as a lawyer. The move eventually brought a big shift in his career when he was asked to assume a general legal role, taking on contract litigation and advising commercial teams.

This experience opened up new areas of the law and business, giving him an opportunity to work with a highly skilled team of Williams & Connolly lawyers on a contract litigation. While surprised at how much he enjoyed working with and learning from the in-house legal team on a variety of issues, taking on new challenges does fit a pattern.

“Generally, I find I am interested in just about everything, and really enjoy working with smart, inquisitive people who are dedicated to bringing potentially life-changing medicines to patients and who are energized by new challenges” Kastenmayer says. “Viela Bio is full of people like that.”

Published on: June 17, 2020



Showcase your feature on your website with a custom “As Featured in Vanguard” badge that links directly to your article!

Copy and paste this script into your page coding (ideally right before the closing tag) where you want to display our review banner.


The piece highlighting my company, Bob Baker Enterprises, Inc., came out fabulous. Our company is in the new and used car sales and service industry. Everyone was great to work with and extremely professional. They produced a high-quality product and have provided expert assistance and guidance post-production of the article.
– Wade Poulson, General Counsel, Bob Baker Enterprises Inc.
It was a great honor to be featured in Vanguard Law. Working with every member of the team, from the initial interview with Erin Clark, through production with Victor Martins, writing the article with Taryn Plumb and creating the final content with Dave Gushee, was a true pleasure. Everyone was very professional, enthusiastic and supportive, and their creative approach and positive attitude clearly came through in the final product.
– Kevin C. Rakowski, Senior Vice President, Deputy General Counsel, Compliance with Radian Group Inc.
I was honored to be the subject of an article. I enjoy reading Vanguard articles and seeing how other attorneys got to their positions and see their jobs. It's also interesting to see how different law firms partner with the subjects of the articles.
– Henry Marquard, in-house counsel, Stanley Consultants Inc.
As promised in advance, my feature in Vanguard has increased my visibility within the profession and prompted more than a few people I have not communicated with recently to reconnect. One of the Italian law firms I have used in the past is now in the process of interviewing me for an article on their website and tweeting out the feature story. Activity and the number of people connecting with me on LinkedIn has soared, which is great. The Vanguard writers and editorial staff were great to work with—highly professional and made the effort to make the experience both fun and rewarding (they were also respectful of the time pressures and demands all lawyers face). I was very pleased with the experience and the final outcome. Needless to say, I have been very pleased. All in all working with Vanguard has been a very positive experience which generated good publicity for both Shawcor and myself. My sincere thanks.
– Tim Hutzul, General Counsel, ShawCor Ltd.


Spring III 2024



  • * We’ll never share your email or info with anyone.
  • This field is for validation purposes and should be left unchanged.